Spectrum of psychiatric adverse reactions to cyclin‐dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system

Documenti analoghi

• Natural compounds from herbs and nutraceuticals as glycogen synthase kinase‐3β inhibitors in Alzheimer's disease treatment
  di: Zheng Zhao, et al.
  Pubblicazione: (2024)
• IL‐4‐JAK1‐STAT6 Pathway Mediates Electroacupuncture's Effect on Microglial M2 Polarization to Treat Inflammatory Bowel Disease With Comorbid Depression
  di: Sihui Cao, et al.
  Pubblicazione: (2025)
• Lymphoplasmapheresis for Steroid‐Refractory Neuromyelitis Optica Spectrum Disorder: A Real‐World Multicenter Study in China
  di: Qiuming Zeng, et al.
  Pubblicazione: (2025)
• Cell‐Type‐Specific WTAP and ALKBH5 ‐Mediated m 6 A Methylation Orchestrates Mental Disorders via Gut‐Brain Axis Metabolite Signaling: Multi‐Omics Evidence and Pyroptosis‐Associated Loop Mechanism
  di: Jingjing Zhang, et al.
  Pubblicazione: (2026)
• SLC38A9 Regulation Affects Hippocampal Neuronal Autophagy: A Potential Alzheimer's Therapeutic Approach by Suppressing Alzheimer's Disease‐Related Protein Deposition
  di: Yixin Chen, et al.
  Pubblicazione: (2026)